ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 992,87
0,00%
Dow Jones
38 686,32
1,51%
DAX
18 497,94
-0,09%
Brent Oil
80,905
0,12%
Bitcoin
68 646,79
1,33%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Angion Biomedica Corporation (ANGN)

  7. Angion Biomedica Corporation (ANGN) Actualités

ANGN

Angion Biomedica (ANGN)

Angion Biomedica Corporation
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ANGN
DateHeureSourceTitreSymboleSociété
29/04/202413h00Edgar (US Regulatory)Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]NASDAQ:ANGNAngion Biomedica Corporation
05/04/202422h33Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ANGNAngion Biomedica Corporation
29/03/202420h28Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ANGNAngion Biomedica Corporation
29/03/202420h26Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ANGNAngion Biomedica Corporation
29/03/202418h58Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ANGNAngion Biomedica Corporation
20/03/202421h37Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:ANGNAngion Biomedica Corporation
20/03/202421h28Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ANGNAngion Biomedica Corporation
05/01/202422h05Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:ANGNAngion Biomedica Corporation
13/11/202314h45Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ANGNAngion Biomedica Corporation
12/08/202303h13Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:ANGNAngion Biomedica Corporation
07/07/202315h17Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ANGNAngion Biomedica Corporation
14/06/202322h05Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:ANGNAngion Biomedica Corporation
14/06/202320h43Edgar (US Regulatory)Statement of Beneficial Ownership (sc 13d)NASDAQ:ANGNAngion Biomedica Corporation
12/06/202323h13Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:ANGNAngion Biomedica Corporation
05/06/202323h26Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ANGNAngion Biomedica Corporation
05/06/202314h01Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ANGNAngion Biomedica Corporation
01/06/202314h00GlobeNewswire Inc.Angion Biomedia Corp. Announces 1-for-10 Reverse Stock SplitNASDAQ:ANGNAngion Biomedica Corporation
24/05/202312h01Edgar (US Regulatory)Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)NASDAQ:ANGNAngion Biomedica Corporation
10/05/202322h14Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:ANGNAngion Biomedica Corporation
28/04/202322h46Edgar (US Regulatory)Amended Annual Report (10-k/a)NASDAQ:ANGNAngion Biomedica Corporation
28/04/202322h14Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:ANGNAngion Biomedica Corporation
17/03/202321h26Edgar (US Regulatory)Annual Report (10-k)NASDAQ:ANGNAngion Biomedica Corporation
14/02/202322h41Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:ANGNAngion Biomedica Corporation
17/01/202311h00GlobeNewswire Inc.Elicio Therapeutics and Angion Enter into Definitive Merger AgreementNASDAQ:ANGNAngion Biomedica Corporation
22/12/202203h50GlobeNewswire Inc.Angion Receives Nasdaq Notice Regarding Minimum Bid Price RequirementsNASDAQ:ANGNAngion Biomedica Corporation
15/08/202222h05GlobeNewswire Inc.Angion Provides Corporate Update and Reports Second Quarter 2022 Financial ResultsNASDAQ:ANGNAngion Biomedica Corporation
26/07/202212h17TipRanksH.C. Wainwright Reiterates Their Hold Rating on Angion Biomedica (ANGN)NASDAQ:ANGNAngion Biomedica Corporation
25/07/202222h30GlobeNewswire Inc.Angion Announces Process to Explore Strategic Alternatives for Enhancing and Preserving Shareholder ValueNASDAQ:ANGNAngion Biomedica Corporation
29/06/202222h05GlobeNewswire Inc.Angion Announces Discontinuation of Phase 2 Trial of ANG-3070 in Patients with Primary Proteinuric Kidney DiseaseNASDAQ:ANGNAngion Biomedica Corporation
27/05/202222h43Edgar (US Regulatory)Amended Statement of Changes in Beneficial Ownership (4/a)NASDAQ:ANGNAngion Biomedica Corporation
 Showing the most relevant articles for your search:NASDAQ:ANGN

Dernières Valeurs Consultées

NASDAQ
PGFMX
Pgim Moderate Retirement...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés